LitCovid-sentences  

PMC:7172841 / 4965-9350 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T40 0-145 Sentence denotes We assessed the differences of immune activation and dysregulation between SARS-CoV-2 and other known severe infections in three patient cohorts:
T41 146-291 Sentence denotes 104 patients with sepsis caused by bacterial CAP; 21 historical patients with 2009 H1N1 influenza; and 54 patients with CAP caused by SARS-CoV-2.
T42 292-453 Sentence denotes Patients with bacterial CAP were screened for participation in a large-scale randomized clinical trial with the acronym PROVIDE (ClinicalTrials.gov NCT03332225).
T43 454-611 Sentence denotes Patients with 2009 H1N1 influenza have been described in previous publications of our group (Giamarellos-Bourboulis et al., 2009, Raftogiannis et al., 2010).
T44 612-725 Sentence denotes The clinical characteristics of patients with bacterial CAP and CAP caused by COVID-19 are described in Table 1 .
T45 726-849 Sentence denotes Each cohort (bacterial sepsis and COVID-19) is split into patients who developed SRF and required MV and those who did not.
T46 850-1571 Sentence denotes Three main features need to be outlined: (1) patients with COVID-19 and SRF are less severe than those with severe bacterial CAP, on the basis of the traditional severity scores of sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation (APACHE) II; (2) this leads to the conclusion that COVID-19 patients undergo an acute immune dysregulation with deterioration into SRF before the overall state of severity is advanced; and (3) although the burden of co-morbidities of patients with COVID-19, as expressed by the Charlson’s co-morbidity index, is higher among patients with SRF than among patients without SRF, it remains remarkably lower that traditional bacterial CAP and sepsis.
T47 1572-1761 Sentence denotes It was also notable that the admission values of Glasgow Coma Scale scores of patients with bacterial CAP were 8.80 ± 4.76, and that of patients with COVID-19 was 14.71 ± 0.20 (p < 0.0001).
T48 1762-1925 Sentence denotes This finding is fully compatible with clinical descriptions of severe COVID-19: patients are admitted at a relatively good clinical state and suddenly deteriorate.
T49 1926-2052 Sentence denotes Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2
T50 2053-2102 Sentence denotes No respiratory failure Severe respiratory failure
T51 2103-2160 Sentence denotes Bacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value
T52 2161-2191 Sentence denotes Number of patients 48 26 56 28
T53 2192-2280 Sentence denotes Age (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 <0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# <0.0001
T54 2281-2355 Sentence denotes Male gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003
T55 2356-2454 Sentence denotes APACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 <0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## <0.0001
T56 2455-2546 Sentence denotes SOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 <0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## <0.0001
T57 2547-2629 Sentence denotes CCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 <0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## <0.0001
T58 2630-2717 Sentence denotes PSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 <0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## <0.0001
T59 2718-2747 Sentence denotes Laboratory values (mean ± SD)
T60 2748-2873 Sentence denotes  Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 <0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## <0.0001
T61 2874-2979 Sentence denotes  Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654
T62 2980-3046 Sentence denotes  INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077
T63 3047-3127 Sentence denotes  aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844
T64 3128-3217 Sentence denotes  Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002
T65 3218-3299 Sentence denotes  D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ <0.0001
T66 3300-3381 Sentence denotes  Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001
T67 3382-3468 Sentence denotes  Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588
T68 3469-3545 Sentence denotes  AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102
T69 3546-3622 Sentence denotes  ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126
T70 3623-3648 Sentence denotes Main comorbidities (n, %)
T71 3649-3726 Sentence denotes  Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214
T72 3727-3800 Sentence denotes  Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114
T73 3801-3871 Sentence denotes  Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0
T74 3872-4021 Sentence denotes Comparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p < 0.05; #p < 0.001; ##p < 0.0001.
T75 4022-4385 Sentence denotes Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment